注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Inhibrx Inc是一家專注於各種生物治療候選藥物的臨床階段生物技術公司。該公司的單域抗體(sdAb)平台提供了一個小型、簡單、模塊化的靶標結合域,可以組合起來以滿足每個生物靶標的需求。其產品線包括:INBRX-101是一種由兩個人類AAT組成的重組α-1抗胰蛋白酶(AAT)蛋白,並由分子共價連接到人類免疫球蛋白G4的可結晶片段(Fc)區域;INBRX-109是一種精確設計的四價sdAb為基礎的靶向死亡受體5(DR5)治療候選藥物,其sdAb平台設計用於驅動癌症選擇性程序性細胞死亡並最大限度地提高效力,同時最大限度地減少肝細胞凋亡引起的靶向肝毒性;INBRX-105是一種精確設計的基於多特異性sdAb的治療候選藥物,旨在在PD-L1存在的情況下選擇性地激動4-1BB。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Guy S. Salvesen | - | - | Scientific Advisor |
Victor Nizet | - | - | Member of Advisory Board |
Douglas Gorman Forsyth | 54 | 2018 | Independent Director |
Kimberly J. Manhard | 63 | 2020 | Independent Director |
Kristiina Vuori | 55 | 2021 | Independent Director |
Mark Brantly | - | 2022 | Member of INBRX-101 Scientific Advisory Board |
Robert A. Sandhaus | - | 2022 | Member of INBRX-101 Scientific Advisory Board |
Rand P. Mulford | 79 | - | Member of Advisory Board |
Stephen B. Howell | 78 | - | Member of Advisory Board |
Mark Paul Lappe | 56 | 2010 | Founder, Chairman, President & CEO |
Igor Barjaktarevic | - | 2022 | Member of INBRX-101 Scientific Advisory Board |
Kenneth R. Chapman | - | 2022 | Member of INBRX-101 Scientific Advisory Board |
John Faiz Kayyem | 59 | 2018 | Independent Director |
James K. Stoller | - | 2022 | Member of INBRX-101 Scientific Advisory Board |
Noel Gerry McElvaney | - | 2022 | Member of INBRX-101 Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核